**HETEROCYCLES, Vol. 59, No. 2, 2003, pp. 485 - 490, Received, 17th September, 2002 A STEREOCONTROLLED SYNTHESIS OF (+)-RHOPALOIC ACID A USING A DIOXABICYCLO[3.2.1]OCTANE CHIRAL BUILDING BLOCK<sup>+</sup>**

## **Kohei Kadota and Kunio Ogasawara\***

Pharmaceutical Institute, Tohoku University, Aobayama, Sendai 980-8578, Japan

**Abstract** – Utilizing a chiral building block having a dioxabicyclo[3.2.1]octane framework, (+)-rhopaloic acid A, a potent cytotoxic norsesterterpene isolated from the marine sponge *Rhopaloeides* sp., has been synthesized in a stereocontrolled manner.

We have developed an efficient preparation of the chiral building block (**2**) having a dioxabicyclo[3.2.1]octane framework in both enantiomeric forms by employing either the Sharpless asymmetric dihydroxylation<sup>1</sup> or the lipase-mediated kinetic resolution<sup>2</sup> as the key step. This chiral building block (**2**) exhibits inherent convex-face selectivity owing to its sterically biased framework to allow diastereocontrolled construction of a variety of biologically active natural products.<sup>3</sup> To extend the versatility of the chiral building block (**2**), we attempted the stereocontrolled synthesis of (+)-rhopaloic acid A (**1**), a potent cytotoxic norsesterterpene having a *trans*-2,5-disubstituted tetrahydropyran core isolated from the marine sponge *Rhopaloeides* sp.<sup>4,5</sup> We wish to report here the successful stereocontrolled transformation of the chiral building block ((+)-**2**) into (+)-rhopaloic acid A (**1**) based on its stereochemical and chemical backgrounds (Scheme 1).





We first carried out the construction of the *trans*-2,5-disubstituted tetrahydropyran core of the target molecule. Thus, the enantiopure enone  $(+)$ - $2^{1,2}$  was transformed into the *exo*-allyl alcohol (4),  $[\alpha]_D^2$  $+119^{\circ}$  (*c* 1.0, CHCl<sub>3</sub>), *via* the *endo*-allyl alcohol (3),  $[\alpha]_D^{30} - 2.8^{\circ}$  (*c* 1.1, CHCl<sub>3</sub>), by sequential convex-

face selective 1,2-reduction and the Mitsunobu inversion employing previously established procedure.<sup>6</sup> After catalytic hydrogenation of the olefin moiety of the allyl alcohol (4), the resulting alcohol (5),  $[\alpha]_D^{\alpha}$ <sup>26</sup>  $-37.1^{\circ}$  (*c* 1.0, CHCl<sub>3</sub>), was transformed into the allyl ether of which silyl ether moiety was then removed to give the primary alcohol (6),  $[\alpha]_D^{26} - 78.4^{\circ}$  (*c* 1.0, CHCl<sub>3</sub>). To cleave the dioxolane moiety, the alcohol (**6**) was transformed into the iodide (**7**),  $[\alpha]_D^2$  +0.1° (*c* 1.1, CHCl<sub>3</sub>), *via* the mesylate. Upon reductive treatment with zinc powder in methanol containing acetic acid, the iodide (**7**) gave the δ-lactol (**8**), as an epimeric mixture, which was immediately reduced with sodium borohydride to give the acyclic dihydroxydiene (9),  $[\alpha]_D^2$  +3.6° (*c* 0.9, CHCl<sub>3</sub>). Ring-closing metathesis<sup>7</sup> of the diene (9) in the presence of a catalytic amount of Grubbs' reagent<sup>8</sup> afforded the expected diol (10) having a 2,3-*trans*-disubstituted dihydropyran framework. Transfer of the *trans*-2,3-stereochemistry of the product (**10**) to the *trans*-2,5 stereochemisty required for the target molecule was next carried out by employing the Eschenmoser rearrangement.<sup>9</sup> Since the Eschenmoser rearrangement of the diol (10) generated a complex mixture of products, its primary hydroxyl functionality was selectively protected to give the *tert*-butyldiphenylsilyl (TBDPS) ether (11),  $[\alpha]_D^2$ <sup>6</sup> –19.0° (*c* 0.9, CHCl<sub>3</sub>), leaving the secondary allyl hydroxyl functionality intact. When the TBDPS ether (**11**) was heated with *N,N*-dimethylacetamide dimethyl acetal in diphenyl ether at reflux (~280 °C), a clean reaction took place to give the 2,5-*trans*-disubstituted dihydropyran



Scheme 2 *Reagents and conditions*: i) NaBH<sub>4</sub>-CeCl<sub>3</sub>-7H<sub>2</sub>O, MeOH (99%). ii) HCO<sub>2</sub>H, *i*- $PrO_2CN=NCO_2Pr-i$ ,  $PPh_3$ , THF, then  $K_2CO_3$ , MeOH (70%). iii)  $H_2$ ,  $PtO_2$ ,  $AcOEt$  (91%). iv) allyl bromide, NaH, THF-DMF (1:1), then Bu<sub>4</sub>NF, THF (92%). v) Ms-Cl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, then LiI, THF, reflux (94%). vi) Zn, AcOH-MeOH (1:9) (97%). vii) NaBH<sub>4</sub>, EtOH (92%). viii) Grubbs' catalyst, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C. ix) TBDPS-Cl, imidazole, DMF (91%, 2 steps). x) Me<sub>2</sub>NC(OMe)<sub>2</sub>Me, Ph<sub>2</sub>O, reflux (92%). xi) H<sub>2</sub>, 10% Pd-C, AcOEt (91%).

 $(12)$ , <sup>10</sup>  $[\alpha]_D^{25}$  +56.2° (*c* 1.1, CHCl<sub>3</sub>), which afforded the tetrahydropyran (13),  $[\alpha]_D^{26}$  +10.3° (*c* 1.0, CHCl3), having the requisite stereochemistry on catalytic hydrogenation. The overall yield of the tetrahydropyran core (**13**) from the starting chiral building block ((+)-**2**) was 37% (Scheme 2).

Having constructed the *trans*-2,5-disubstituted tetrahydropyran core (**13**) of the target molecule (**1**), we next carried out transformation of its 2,5-functionalities into the actual functionalities of the target natural product (**1**), respectively. Thus, one extra oxygen atom was first introduced on the C-2 functionality to give the dioxolane (**16**) to prepare for the final construction of the C-2 functionality *via* the primary alcohol (14),  $[\alpha]_D^2$ <sup>24</sup> +11.7° (*c* 1.1, CHCl<sub>3</sub>), and the 2-allyl intermediate (15) by sequential desilylation, the Grieco dehydration, $11$  dihydroxylation and ketalization.

We then carried out the construction of the C-5 triene moiety of the target molecule at this stage. Stereocontrolled introduction of the two *E*-trisubstituted olefins in the C-5 functionality was carried out by employing the methodology developed by Johnson and co-workers<sup>12</sup> in the synthesis of squalene but using *N,N*-dimethylacetamide dimethyl acetal under neutral conditions in place of triethyl orthoacetate which was used in the Johnson synthesis in the presence of an acid catalyst. Thus, the tertiary amide (**16**) was transformed into the primary alcohol (**17**) in one step on treatment with lithium triethylborohydride (Super Hydride) in THF.<sup>13</sup> Under standard conditions the hydroxyl functionality was replaced by the cyano functionality *via* the bromide<sup>14</sup> (18) and the resulting cyanide (19) was transformed into the aldehyde (**20**) by partial reduction with diisobutylaluminum hydride (DIBAL). Treatment of the aldehyde (**20**) with isopropenylmagnesium bromide in THF afforded the allyl alcohol (**21**) which was heated with *N,N*-dimethylacetamide dimethyl acetal in diphenyl ether at reflux to give the γ,δ-unsaturated amide (**22**) having *E*-configuration<sup>12</sup> selectively through a [3,3] sigmatropic rearrangement.<sup>9</sup> The resulting tertiary amide (**22**) was then transformed into the enal (**24)** *via* the primary alcohol (**23)** by sequential reduction with lithium triethylborohydride<sup>14</sup> and the Swern oxidation.<sup>14</sup> Upon the reiteration of the same four steps of sequence above involving the Grignard reaction, the Eschenmoser [3,3] sigmatropic rearrangement, the lithium triethylborohydride-mediated reduction and the Swern oxidation, the aldehyde (**24**) furnished the dienal (**28**) as the single product *via* the allyl alcohol (**25**), the tertiary amide (**26**) and the primary alcohol (**27**). Finally, the aldehyde (**28**) was treated with the Wittig reagent to give the triene (**29**) to complete the installation of the C-5 functionality.

To complete the synthesis of the target natural product, the dioxolane moiety of the triene (**29**) thus obtained was hydrolyzed at this stage under acidic conditions to generate the 1,2-glycol which was cleaved with sodium periodate to give the aldehyde (30),  $[\alpha]_D^{\beta_1}$  +7.5° (*c* 0.5, CHCl<sub>3</sub>). Upon treatment with dimethylmethyleneammonium chloride<sup>16</sup> in dichloromethane in the presence of triethylamine, the aldehyde (30) furnished the  $\alpha$ -methylidene aldehyde (31),  $[\alpha]_D^{29}$  +40.6° (*c* 0.5, CHCl<sub>3</sub>), by concurrent

Mannich and elimination reactions as expected on the basis of our previous observation.<sup>17</sup> Finally, the α,β-unsaturated aldehyde (**31**) was oxidized<sup>18</sup> to afford the target natural product (–)-rhopaloic acid A (**1**), [ $\alpha$ ]<sub>D</sub><sup>29</sup> +41.3° (*c* 0.2, CHCl<sub>3</sub>)<sup>19</sup>{natural<sup>4</sup>: [ $\alpha$ ]<sub>D</sub><sup>25</sup> +40° (*c* 0.47, CHCl<sub>3</sub>)}. The overall yield of the natural product from the tetrahydropyran intermediate (**13**) was 5%, and, thus, 2% from the starting chiral building block  $((+)$ -2) (Scheme 3).



Scheme 3 *Reagents and conditions*: i)  $Bu_4NF$ , THF (100%). ii)  $o-(NO_2)C_6H_4SeCN$ ,  $Bu_3P$ , THF, then 30% H<sub>2</sub>O<sub>2</sub>, THF. iii) OsO<sub>4</sub>(cat.), NMO, 50% aq. THF, then Me<sub>2</sub>C(OMe)<sub>2</sub>, PPTS, toluene, 100 °C (70%, 4 steps). iv) LiEt<sub>3</sub>BH, THF, -30 °C (95%). v) NBS, PPh<sub>3</sub>, pyridine, CH<sub>2</sub>Cl<sub>2</sub> (88%). vi) KCN, DMSO (100%). vii) DIBAL, CH<sub>2</sub>Cl<sub>2</sub>,  $-78~0$  °C, aqueous workup (84%). viii) isopropenyl-MgBr, THF,  $-78-40$  °C. ix) Me<sub>2</sub>NC(OMe)<sub>2</sub>Me, Ph<sub>2</sub>O, reflux (55% for **22**; 56% for **26**, 2 steps). x) LiEt<sub>3</sub>BH, THF,  $-30$   $-0$  °C, then Swern oxidation (76% for **24**;75% for **28**, 2 steps). xi) *i*-PrPPh<sub>3</sub>I, BuLi, THF, 0 °C (63%). xii)  $CF_3CO_2H$ , 20% aq.THF, then NaIO<sub>4</sub>, 50% aq.THF (97%). xiii)  $CH_2=NMe_2Cl$ ,  $Et_3N$ ,  $CH_2Cl_2$  (93%). xiv) NaClO2, NaH2PO4, 2-methylbut-2-ene, 90% aq. *t*-BuOH (96%).

In conclusion, we have demonstrated a new utilization of our dioxabicyclo[3.2.1]octnane chiral building block by a stereocontrolled synthesis of a potent cytotoxic norsesterterpene (–)-rhopaloic acid isolated from the marine sponge *Rhopaloeides* sp. using the (+)-enantiomer and have extended the versatility of our chiral building block.

## **ACKNOWLEDGEMENTS**

We are grateful to the Ministry of Education, Culture, Sports, Science and Technology, Japan for support of this work. We thank Professor Yoshiharu Iwabuchi, Pharmaceutical Institute, Tohoku University, for helpful suggestions.

## **REFERENCES**

 $+$  Dedicated to Professor Yuichi Kanaoka on the occasion of his  $75<sup>th</sup>$  birthday.

- 1. M. Takeuchi, T. Taniguchi, and K. Ogasawara, *Synthesis,* 1999, 341.
- 2. T. Taniguchi, M. Takeuchi, K. Kadota, A. S. ElAzab, and K. Ogasawara, *Synthesis,* 1999, 1325.
- 3. For a pertinent review for utilization of the compound (**2**) as a versatile chiral building block, see: K. Ogasawara, *J. Syn. Org. Chem. Jpn*., 2002, **60**, 316.
- 4. Isolation: S. Ohta, M. Uno, M. Yoshimura, Y. Hiraga, and S. Ikegami, *Tetrahedron Lett*., 1996, **37**, 2265.
- 5. For racemic syntheses, see: a) B. B. Snider and F. He, *Tetrahedron Lett*., 1977, **38**, 5453. b) R. Takagi, A. Sasaoka, S. Kojima, and K. Ohkata, *Heterocycles,* 1997, **45**, 2313. For racemic and non-racemic syntheses, see: c) R. Takagi, A. Sasaoka, S. Kojima, and K. Ohkata, *Chem. Commun*., 1997, 1887. d) R. Takagi, A. Sasaoka, H. Nishitani, S. Kojima, Y. Hiraga, and K. Ohkata, *J. Chem. Soc., Perkin Trans. 1,* 1998, 925.
- 6. K. Kadota, T. Taniguchi, and K. Ogasawara, *Synlett,* 2002, 334.
- 7. For pertinent reviews, see: a) R. H. Grubbs and S. Chang, *Tetrahedron,* 1998, **54**, 4413. b) R. Roy and S. K. Das, *Chem. Commun*., 2000, 519. c) A. Fürstner, *Angew. Chem., Int. Ed.,* 2000, **39**, 3012. d) T. M. Trnka and R. H. Grubbs, *Acc. Chem. Res*., 2001, **34**, 18.
- 8. Bis(tricyclohexylphosphine)benzylideneruthenium(IV) dichloride was purchased from Strem Chemicals and used without further purification.
- 9. A. E. Wick, D. Felix, K. Steen, and A. Eschenmoser, *Helv. Chim. Acta,* 1964, **47**, 2425.
- 10. T. Taniguchi and K. Ogasawara, *Org. Lett.,* 2000, **2**, 3193.
- 11. P. A. Grieco, S. Gilman, and M. Nishizawa, *J. Org. Chem*., 1976, **41**, 1485.
- 12. W. S. Johnson, L. Werthemann, W. R. Bartlett, T. J. Brocksom, T. –t. Li, D. J. Faulkner, and M. R.

Petersen, *J. Am. Chem. Soc.,* 1970, **92**, 741.

- 13. H. C. Brown, S. C. Kim, and S. J. Krishnamurthy, *J. Org. Chem*., 1980, **45**, 1.
- 14. J. K. Dickson Jr., R. Tsang, J. M. Llera, J. M. and B. Fraser-Reid, *J. Org. Chem*., 1989, **54**, 5350.
- 15. A. J. Mancuso and D. Swern, *Synthesis,* 1981, 165.
- 16. H. Böhme and K. Hartke, *Chem. Ber*., 1960, **93**, 1305.
- 17. S. Takano, K. Inomata, K. Samizu, S. Tomita, M. Yanase, M. Suzuki, Y. Iwabuchi, T. Sugihara, and K. Ogasawara, *Chem. Lett*., 1989, 1283.
- 18. B. Lindgren and T. Nilsson, *Acta Chem. Scand*., **1973**, *27*, 888.
- 19. Spectroscopic data  $\text{(IR, }\,{}^1\text{H}$  and  ${}^{13}\text{C}$  NMR, and MS) were identical with those reported to the natural product. 4